The upcoming SMC appraisal is crucial if bosutinib is going to be available to CML patients in Scotland and given the recent NICE ACD which does not recommend bosutinib for treatment in England (we are currently writing our response to the ACD) at least the drug is available through the Cancer Drugs Fund.
Things might have changed but we understand that in Scotland although there is a rare drugs fund, the fund is not large, is for all rare diseases not only cancers and is for only one year.
CMLS Group are committed to the view that all patients throughout the UK should have access to all current TKIs and will continue to argue for the need for choice.
If you are currently treated in Scotland with bosutinib (or know someone who is) and would be willing to write a short submission (200 words) to the SMC outlining your previous and present treatment experience - how you are responding to your therapy etc. - please contact me either through this forum or on cmlsupportgroup@gmail.com
Thanks,
Sandy